You can copy and paste this URL.
This URL will permanently link back to this page.
New Technology Stocks Added to TSA Portfolio:
Raleigh, N.C. The Technology Stock Advisor, a weekly internet newsletter covering investments in high technology stocks, initiated coverage today on two stocks. Both stocks were added to the TSA C Stock Portfolio, which means that they have more price volatility than stocks rated in the B or A portfolios.
LeMaitre Vascular, Inc. develops, manufactures, and markets vascular devices for the treatment of peripheral vascular disease worldwide. The company provides vascular products, including balloon catheters for the removal of blood clots, occlusion, and facilitation of blood flow; carotid shunts for the facilitation of blood flow to brain during carotid plaque removal; remote endarterectomy devices for the removal of blockages in the major arteries of the leg; and valvulotomes for the destruction of vein valves to create vein bypass grafts.
Vicor Corporation, together with its subsidiaries, engages in the design, development, manufacture, and marketing of modular power components and power systems. It offers a range of high current density/low voltage DC-DC converters, bus converters, and individual models for regulation and transformation; configurable products that provide power solutions configured to customers’ specific needs; factorized power architecture products; and custom power solutions.
All of the stocks mentioned in the TSA Newsletter were selected based upon a 2007 stock selection and asset allocation patent issued to Thomas Vass, the investment advisor to the newsletter. The method of the patent explains what stocks to buy, the target buy price, the target sell price and the best asset allocation for an investor’s risk profile. After a stock has been selected. It is added to one of three TSA portfolios, based upon its quality rating, as provided by Standard & Poors®.
“Our patented stock screening methodology begins by searchingfor technology companies in nine high technology value chains,” said Vass.
The nine technology value chain categories being investigated by TSA are:
“As a result of their production relationships within these clusters, we suspect that Vicor Corporation and LeMaitre Vascular are prime candidates for product innovation,” said Vass. “As a result of their product innovation today, we suspect that new markets may evolve for their products in the future that may have the potential for causing their stock price appreciation,” he said.
Investment Disclosure: The past performance of an investment is no guarantee of future performance. All investments bear risk of loss of principal invested. There are no guarantees related to investing. Please visit the TSA website and read our ADV Part II disclosure document for information about our investment management fees.
This new Article is not yet ready for syndication. Please check back in a few minutes.
This Article is not available for syndication. Contact BestThinking for details.
Enjoy high quality content through BestThinking's syndication program. Learn more and register as a publisher today!
Enhance your publication, blog or journal with high quality content from BestThinking. Whether you are looking for a single feature article, a stream of dynamic content or just a few pieces each month, BestThinking's unique, customizable syndication feeds provide rights-verified material from identity verified Thinkers.
To syndicate a Blog or Article, you’ll need to start by setting up a feed. Creating a feed is a 3-step process:
About the Author
I help CEOs of small technology companies raise capital by providing outsourced services during a six month consulting engagement where I ma
“At any moment along the three year future stock price pathway,” said Vass, “a C rated stock could be down as much as 40% from the initial purchase price.”
We apply an analysis and screening of the financial strength of the stocks, based upon variables that we suspect will influence the stock price,” he added. “In the case of EVOL, we are attracted to the very attractive dividend yield of over 4%, in addition to the other factors which make this a very
“Hawkins provides essential intermediate inputs to the biotech and pharma industrial cluster, as well as to the entire agri food cluster,” said Vass.